10 October 2016 - Statements linking a price increase of Panadol Osteo to its removal from the Pharmaceutical Benefits Scheme were "ambiguous" but not misleading, an investigation by the Australian Competition and Consumer Commission has found.

In December last year,  GlaxoSmithKline told its wholesalers it would lift its prices for Panadol Osteo by 50 per cent from January 1.

The hike meant the cost of one box rose to $7.50, if pharmacies passed on the full price rise to consumers.

It followed a government announcement in November that a number of medicines would be removed from the Pharmaceutical Benefits Scheme, if they were also available over-the-counter and cost less than the standard co-payment amount, including paracetamol products.

Read Sydney Morning Herald article